Fred Van LeuvenPh.D., DrSc.,
Fred Van Leuven is professor ordinarius in the Faculty of Medicine, University of Leuven. He earned a M.Sc. in biochemistry (1970, University of Ghent) and a Dr.Sc. in physiology on brain glutamate/glutamine metabolism (1976, University of Ghent) before moving to the Dept of Human Genetics, University of Leuven as post-doc. In 1986 he earned his "Aggregate HSO" ('Habilitation', Ph.D.) on the cell-biology of A2M and its receptor LRP1.
Fred Van Leuven founded the research-group LEGTEGG to introduce transgenic animal technology in Flanders (1988) first to produce knock-out mice lacking A2M and family-members. The interest in Amyloid Precursor Protein (APP) in transgenic mouse models for Alzheimer's disease was supported by the Flemish Action for Biotechnology (1993-1995), and led to the participation in the first term of the Flemish Institute for Biotechnolgy (VIB) (1995-2000). He is recognized as a world authority on mouse models for Alzheimer's disease, to recapitulate in vivo amyloid and tau pathology, separately and combined, and for the role of the GSK3 kinases in brain. He produced nearly 300 scientific publications in international, peer-reviewed journals.
After co-founding reMYND in 2002, he co-founded ACImmune SA (°2003, Strasbourg / Lausanne) a privately owned biotech company dedicated to the development of innovative therapies for Alzheimer´s Disease. He is SAB-member of ACImmune, member of learned societies, reviewer for journals and referee and board-member of international sponsoring agencies in neuroscience and neurodegenerative disease.
Stefaan Wera founded reMYND in 2002 together with Fred Van Leuven, Joris Winderickx and Paul van Dun. Stefaan studied biological sciences at the University of Leuven, Belgium where he also obtained his Ph.D. degree in 1992. After a postdoctoral position at the Laboratoire de Biologie Moléculaire at the University of Liège, Belgium (1992-1993), he was awarded an EMBO-fellowship at the Friedrich-Miescher Institut in Basel, Switzerland (1993-1994). He continued research as an FWO post-doctoral fellow at the Biochemistry Department and the Laboratory for Molecular Cell Biology (University of Leuven) until 2001.
Stefaan managed reMYND as Chief Executive Officer from start-up until late 2007 in which time the company developed contract research activities and ran a successful drug discovery and development program in the field of Alzheimer’s and Parkinson’s disease. In 2007 Stefaan co-founded Okapi Sciences (http://www.okapi-sciences.com).
Joris WinderickxProf. Dr.,
Joris Winderickx is an expert cell biologist. He co-founded reMYND together with Fred Van Leuven, Stefaan Wera and Paul Van Dun. After a post-doc at the U. Washington, Seattle, in the Dept. of Genetics and Dept. of Human Genetics, Joris became full professor at the University of Leuven where he heads the Functional Biology group (http://www.kuleuven.be/bio/funbio). The research in his team is focused on the elucidation of signal transduction mechanisms required to control cellular metabolism, growth and survival. This led to the development of so-called humanized yeast models allowing to study crucial aspects related to a variety of human pathologies in a less complex but biologically relevant model system.
Joris was recently appointed as chairman and coordinator of LBioSCENTer, an association of the University of Leuven laboratories with dedicated research on bioscience, bioengineering and biotechnology (http://www.kuleuven.be/bioscenter). He also co-founded the Royal Flemish Society of Chemistry-section Biotechnology and the alumni-association Science@Leuven.